Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Methylone is a synthetic cathinone and entactogen structurally related to MDMA (3,4-methylenedioxymethamphetamine), often described as its beta-keto analog. It acts primarily as a substrate for monoamine transporters—dopamine transporter (DAT), norepinephrine transporter (NET), and serotonin transporter (SERT)—promoting the release of dopamine, norepinephrine, and serotonin into the synaptic cleft. This results in stimulant and empathogenic effects similar to those of MDMA but with some pharmacological differences; notably methylone releases less dopamine than MDMA but comparable levels of norepinephrine and serotonin[2][3][6]. Preclinical studies suggest rapid-acting antidepressant- and anxiolytic-like effects in animal models[7], with emerging interest in its potential for treating major depressive disorder (MDD) and post-traumatic stress disorder (PTSD)[8]. Methylone is not approved for medical use; it has been used recreationally as a "designer drug" or "bath salt" substitute for MDMA[1][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on methylone.